FARASTAR Pulsed Field Ablation (PFA) Generator; FARASTAR Mapping System Module (MSM); FARASTAR Recording System Modul
Farapulse, Inc. · Decision date Sep 4, 2026
What did the FDA approve?
FDA recorded an approval decision on 2026-09-04 for P230030/S024, a real-time process supplement to PMA P230030 held by Farapulse, Inc. The supplement reason is a change in design, components, specifications or material. The recorded statement covers FARASTAR PFA Generator Software 4.5.3/4.6.3, the FARASTAR Foot Switch, and updates to the FARASTAR System Instructions for Use.
The parent filing covers a percutaneous cardiac ablation catheter for atrial fibrillation using irreversible electroporation, in the cardiovascular specialty under product code QZI. This supplement addresses the named software, accessory and labeling items rather than a new approval of the whole system. The source record does not include the decision documents, so the specific technical changes and any conditions of approval remain unknown.
The title field also lists a Mapping System Module and a Recording System Module, but the statement does not describe changes to them, so their status in this supplement is unclear.
FDA approval order statement
approval for FARASTAR PFA Generator Software 4.5.3/4.6.3, FARASTAR Foot Switch, and updates to the FARASTAR System Instructions for Use
- Regulatory pathway
- PMA supplement
- Supplement type
- Real-Time Process
- Clinical specialty
- Cardiovascular
- Decision date
- Sep 4, 2026
- FDA change category
- Change Design/Components/Specifications/Material
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P230030/S024
- Regulatory pathway
- PMA supplement
- Applicant
- Farapulse, Inc.
- Product code
- QZI
- Decision code
- APPR
- Decision date
- Sep 4, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Percutaneous Cardiac Ablation Catheter for Treatment of Atrial Fibrillation with Irreversible Electroporation.
- Applicant
- Farapulse, Inc.
- Product code
- QZI
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P230030. Subsequent supplements may change the device or its indications.
FDA decision timeline
P230030 · Original PMA
FARAPULSE Pulsed Field Ablation System (FARAWAVE Pulsed Field Ablation Catheter, FARASTAR Catheter Connection Cable,
P230030/S024 received
Application receipt date recorded by FDA.
P230030/S024 · FDA decision
Real-Time Process
P230030/S025 · Related supplement
FARAPULSE Pulsed Field Ablation System (FARAWAVE Pulsed Field Ablation Catheter, FARASTAR Catheter Connection Cable,
Timeline entries are records held by MedtechLedger for P230030. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P230030
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Farapulse, Inc. | PMA approval | Jan 30, 2024 | FDA | |
| Farapulse, Inc. | PMA supplement | Oct 2, 2026 | FDA |
Explore the linked device profile
Other records with product code QZI
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Varipulse Bi-Directional CatheterP240006/S018 | Biosense Webster, Inc. | PMA supplement | Nov 3, 2026 | FDA |
Globe Catheter and Globe Pulsed Field SystemP240044/S007 | Kardium, Inc. | PMA supplement | Oct 27, 2026 | FDA |
Globe Pulsed Field System; Globe CatheterP240044/S008 | Kardium, Inc. | PMA supplement | Oct 23, 2026 | FDA |
Volt PFA SystemP250022/S002 | ABBOTT MEDICAL | PMA supplement | Oct 15, 2026 | FDA |
Affera Sphere-9 Mapping and Ablation CatheterP240013/S032 | Medtronic, Inc. | PMA supplement | Oct 9, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Farapulse, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 3715 Haven Ave., Suite 110, Menlo Park, CA, 94025
Sources and methodology
- Original FDA record: P230030/S024
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
